Chemoresistance in pancreatic cancer
S Zeng, M Pöttler, B Lan, R Grützmann… - International journal of …, 2019 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC), generally known as pancreatic cancer (PC),
ranks the fourth leading cause of cancer-related deaths in the western world. While the …
ranks the fourth leading cause of cancer-related deaths in the western world. While the …
New treatment strategies for metastatic pancreatic ductal adenocarcinoma
RR Singh, EM O'Reilly - Drugs, 2020 - Springer
Pancreatic ductal adenocarcinoma (PDAC) is typically diagnosed at an advanced stage,
with systemic therapy being the mainstay of treatment. Survival continues to be limited …
with systemic therapy being the mainstay of treatment. Survival continues to be limited …
Comparison of FOLFIRINOX vs gemcitabine plus nab-paclitaxel as first-line chemotherapy for metastatic pancreatic ductal adenocarcinoma
A Klein-Brill, S Amar-Farkash, G Lawrence… - JAMA network …, 2022 - jamanetwork.com
Importance FOLFIRINOX (leucovorin calcium [folinic acid], fluorouracil, irinotecan
hydrochloride, and oxaliplatin) and gemcitabine plus nab-paclitaxel are the 2 common first …
hydrochloride, and oxaliplatin) and gemcitabine plus nab-paclitaxel are the 2 common first …
[HTML][HTML] GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer
C Pecoraro, B Faggion, B Balboni, D Carbone… - Drug Resistance …, 2021 - Elsevier
Pancreatic cancer is an aggressive malignancy with increasing incidence and poor
prognosis due to its late diagnosis and intrinsic chemoresistance. Most pancreatic cancer …
prognosis due to its late diagnosis and intrinsic chemoresistance. Most pancreatic cancer …
A phase 3 randomized clinical trial of chemotherapy with or without algenpantucel-L (hyperacute-pancreas) immunotherapy in subjects with borderline resectable or …
Objectives: To compare the efficacy and safety of algenpantucel-L [HyperAcute-Pancreas
algenpantucel-L (HAPa); IND# 12311] immunotherapy combined with standard of care …
algenpantucel-L (HAPa); IND# 12311] immunotherapy combined with standard of care …
NALIRIFOX, FOLFIRINOX, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer: a systematic review and meta-analysis
F Nichetti, S Rota, P Ambrosini, C Pircher… - JAMA Network …, 2024 - jamanetwork.com
Importance The NAPOLI 3 trial showed the superiority of fluorouracil, leucovorin, liposomal
irinotecan, and oxaliplatin (NALIRIFOX) over the combination of gemcitabine and nab …
irinotecan, and oxaliplatin (NALIRIFOX) over the combination of gemcitabine and nab …
[HTML][HTML] Inhibition of PI3K/AKT signaling via ROS regulation is involved in Rhein-induced apoptosis and enhancement of oxaliplatin sensitivity in pancreatic cancer …
Y Liu, C Shi, Z He, F Zhu, M Wang, R He… - … Journal of Biological …, 2021 - ncbi.nlm.nih.gov
Several natural products have been demonstrated to both enhance the anti-tumor efficacy
and alleviate the side effects of conventional chemotherapy drugs. Rhein, a main constituent …
and alleviate the side effects of conventional chemotherapy drugs. Rhein, a main constituent …
Emerging role of targeted therapy in metastatic pancreatic adenocarcinoma
BM Huffman, H Ellis, AC Jordan, WA Freed-Pastor… - Cancers, 2022 - mdpi.com
Simple Summary Metastatic pancreatic ductal adenocarcinoma (PDAC) is an aggressive
malignancy that has limited treatment options. Standard of care treatment involves systemic …
malignancy that has limited treatment options. Standard of care treatment involves systemic …
Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching …
JW Chun, SH Lee, JS Kim, N Park, G Huh, IR Cho… - BMC cancer, 2021 - Springer
Abstract Background FOLFIRINOX (FFX) and Gemcitabine plus nab-paclitaxel (GnP) have
been recommended as the first-line chemotherapy for metastatic pancreatic cancer (mPC) …
been recommended as the first-line chemotherapy for metastatic pancreatic cancer (mPC) …
Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis
F Petrelli, A Parisi, G Tomasello, E Mini, M Arru… - BMC …, 2023 - Springer
Background In metastatic pancreatic ductal adenocarcinoma (mPDAC), first line treatment
options usually include combination regimens of folinic acid, 5-fluorouracil (5-FU) …
options usually include combination regimens of folinic acid, 5-fluorouracil (5-FU) …